FGEN and AZN Related Headlines
Go Back- FibroGen (FGEN) announces FDA will hold an advisory committee meeting to review the new drug application for roxadustat
- FibroGen Provides Regulatory Update on Roxadustat
- FibroGen (FGEN) to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at ASH
- FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting
- FibroGen (FGEN) to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week
- FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
FGEN and AZN Related Press Releases
Go Back- FibroGen Provides Regulatory Update on Roxadustat
- FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting
- FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined